Last Updated:
10 Mar 2026, 03:29:57 PM (IST)
Themis Medicare Limited
NSE: THEMISMED BSE: THEMISMED
NSE
81.71
4.82 (6.27%)
Prev Close
76.89
Open Price
77.26
Volume
115,125
Today Low / High
77.26 / 83.1
52 WK Low / High
74.06 / 176
Range
78 - 86
BSE
81.36
4.78 (6.24%)
Prev Close
76.58
Open Price
78.8
Volume
6,655
Today Low / High
78.63 / 83.07
52 WK Low / High
73.79 / 179.25
Range
77 - 85
The stock is currently trading on both the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE). On the NSE, the stock is priced at 81.71 (target range: 78 - 86), reflecting a change of 4.82 (6.2687%). On the BSE, it is listed at 81.36 (target range: 77 - 85), showing a change of 4.78 (6.24184%). Both the NSE and BSE data indicate positive movement, suggesting the stock is on an upward trend. This could be an attractive opportunity for investors looking for growth.
Themis Medicare Limited Graph
Themis Medicare Limited Price Target Predictions: Bullish vs. Bearish Scenarios with Ranges
If you are looking for the target price for Themis Medicare Limited T1, T2, T3 for both Bullish and Bearish scenarios, here it is. For Bullish: T1, T2, T3. For Bearish: T1, T2, T3. The stock current price is 81.71, with potential price targets ranging from T1, T2, and T3 in both directions based on market conditions.
| Scenario | Price | Target | Range |
|---|---|---|---|
| Bullish Scenario | 81.36 | 82.17 | 73.96 - 90.39 |
| 82.99 | 66.39 - 99.58 | ||
| 83.80 | 58.66 - 108.94 | ||
| Bearish Scenario | 81.36 | 80.55 | 72.49 - 88.60 |
| 79.73 | 63.79 - 95.68 | ||
| 78.92 | 55.24 - 102.59 |
Overview of Themis Medicare Limited
ISIN
INE083B01024
Industry
Drug Manufacturers - Specialty & Generic
Vol.Avg
75,226
Market Cap
7,612,994,266
Last Dividend
0.5
Official Website
IPO Date
2007-04-02
DCF Diff
24.01
DCF
67
Financial Ratios Every Investor Needs
Stock Dividend of THEMISMED
| Date | Label | Adj Dividend | Dividend | Record Date | Payment Date | Declaration Date |
|---|---|---|---|---|---|---|
| 2025-09-04 | September 04, 25 | 0.5 | 0.5 | 2025-09-05 | 2025-10-12 | |
| 2024-07-12 | July 12, 24 | 0.5 | 0.5 | 2024-07-13 | 2024-08-21 | |
| 2023-09-01 | September 01, 23 | 0.5 | 5 | 2023-09-01 | 2023-10-09 | |
| 2022-09-08 | September 08, 22 | 0.5 | 5 | 2022-09-10 | 2022-10-19 | |
| 2021-09-08 | September 08, 21 | 0.43 | 4.3 | 2021-09-10 | 2021-10-18 |
Annual Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | R&D Expenses | G&A Expenses | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 405.51 Cr | 131.99 Cr | 273.52 Cr | 0.6745 | 13.21 Cr | 99.83 Cr | 39.15 Cr | 29.83 Cr | 3.24 | 49.05 Cr | 0.0736 |
| 2024-03-31 | 381.76 Cr | 139.76 Cr | 242.00 Cr | 0.6339 | 12.79 Cr | 84.58 Cr | 130.31 Cr | 43.52 Cr | 4.73 | 73.32 Cr | 0.1140 |
| 2023-03-31 | 354.32 Cr | 118.36 Cr | 235.96 Cr | 0.6659 | 12.60 Cr | 9.34 Cr | 56.96 Cr | 56.90 Cr | 6.18 | 78.96 Cr | 0.1606 |
| 2022-03-31 | 394.61 Cr | 151.99 Cr | 242.62 Cr | 0.6148 | 10.12 Cr | 9.92 Cr | 86.16 Cr | 72.88 Cr | 7.92 | 102.18 Cr | 0.1847 |
| 2021-03-31 | 230.67 Cr | 80.53 Cr | 150.14 Cr | 0.6509 | 8.50 Cr | 6.69 Cr | 40.95 Cr | 35.70 Cr | 3.89 | 53.12 Cr | 0.1548 |
Annual Financials Balance Sheet
| Date | C&C Equ. | Tot. Assets | Tot. Liab. | Stock. Equity | Tot. Debt | Net Debt | Inv. | PP&E (Net) | Curr. Def. Rev. | Non-Curr. Def. Rev. | LT Invest. | Curr. Liab. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 6.56 Cr | 588.03 Cr | 185.43 Cr | 402.6011 Cr | 82.99 Cr | 70.15 Cr | 84.31 Cr | 174.54 Cr | 0.35 Cr | 0.00 Cr | 95.95 Cr | 156.1246 Cr |
| 2024-03-31 | 9.92 Cr | 566.42 Cr | 188.75 Cr | 377.6666 Cr | 95.79 Cr | 85.87 Cr | 70.57 Cr | 170.42 Cr | 7.42 Cr | 0.00 Cr | 89.81 Cr | 154.5846 Cr |
| 2023-03-31 | 12.55 Cr | 513.96 Cr | 174.51 Cr | 339.4423 Cr | 92.38 Cr | 79.83 Cr | 68.95 Cr | 164.03 Cr | 34.49 Cr | -6.94 Cr | 59.10 Cr | 139.1285 Cr |
| 2022-03-31 | 20.28 Cr | 427.78 Cr | 140.29 Cr | 287.4891 Cr | 79.73 Cr | 59.45 Cr | 60.81 Cr | 145.57 Cr | 22.17 Cr | -6.47 Cr | 46.97 Cr | 109.5186 Cr |
| 2021-03-31 | 19.02 Cr | 371.14 Cr | 152.63 Cr | 218.5068 Cr | 87.18 Cr | 68.16 Cr | 58.49 Cr | 134.37 Cr | 33.67 Cr | 0.00 Cr | 34.30 Cr | 128.3061 Cr |
Annual Financials Cash Flow Statement
| Date | Operating Cash | Investing Cash | Financing Cash | Free Cash | Cash Change | Cash at End | CapEx | Income | Debt Repay | Dividends | Inventory |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 34.7101 Cr | -12.1744 Cr | -25.8980 Cr | 19.2837 Cr | -3.3623 Cr | 6.5594 Cr | -15.4264 Cr | 29.8330 Cr | -12.8037 Cr | -4.6020 Cr | -13.7402 Cr |
| 2024-03-31 | 22.0936 Cr | -15.9480 Cr | -8.7704 Cr | 3.6757 Cr | -2.6248 Cr | 9.9217 Cr | -18.4179 Cr | 43.5238 Cr | 3.8361 Cr | -4.6014 Cr | -1.6223 Cr |
| 2023-03-31 | 16.0925 Cr | -23.9615 Cr | 0.1362 Cr | -12.6554 Cr | -7.7328 Cr | 12.5465 Cr | -28.7479 Cr | 72.5149 Cr | 13.4063 Cr | -4.6001 Cr | -8.1426 Cr |
| 2022-03-31 | 34.3941 Cr | -15.5859 Cr | -17.5469 Cr | 13.7668 Cr | 1.2613 Cr | 20.2793 Cr | -20.6273 Cr | 95.2620 Cr | -6.6066 Cr | -3.9558 Cr | -2.3150 Cr |
| 2021-03-31 | 56.9751 Cr | -15.6512 Cr | -25.6474 Cr | 38.9363 Cr | 15.6765 Cr | 19.0180 Cr | -18.0388 Cr | 41.3307 Cr | -12.4286 Cr | -1.6079 Cr | -3.8855 Cr |
Quarterly Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|
| 2025-12-31 | 90.13 Cr | 54.45 Cr | 35.69 Cr | 0.3959 | 7.21 Cr | 10.09 Cr | 1.10 | 9.80 Cr | 0.1120 |
| 2025-09-30 | 77.99 Cr | 24.15 Cr | 53.85 Cr | 0.6904 | -5.66 Cr | -3.62 Cr | -0.39 | 1.89 Cr | -0.0464 |
| 2025-06-30 | 97.58 Cr | 52.40 Cr | 45.18 Cr | 0.4630 | -12.63 Cr | -14.22 Cr | -1.54 | -9.04 Cr | -0.1457 |
| 2025-03-31 | 71.70 Cr | 20.59 Cr | 51.11 Cr | 0.7129 | -8.32 Cr | -9.66 Cr | -1.05 | -9.80 Cr | -0.1348 |
| 2024-12-31 | 93.81 Cr | 28.50 Cr | 65.31 Cr | 0.6962 | 5.99 Cr | 0.52 Cr | 0.06 | 6.99 Cr | 0.0055 |
Quarterly Financials Balance Sheet
| Date | Cash & Equiv. | Short-Term Inv. | Cash & Short-Term | Net Receivables | Inventory | Total Curr. Assets | PP&E (Net) | Total Assets | Total Liabilities |
|---|---|---|---|---|---|---|---|---|---|
| 2025-09-30 | 8.13 Cr | 10.83 Cr | 18.96 Cr | 173.43 Cr | 76.45 Cr | 299.00 Cr | 172.07 Cr | 582.50 Cr | 202.49 Cr |
| 2025-06-30 | 0.00 Cr | 0.00 Cr | 12.84 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | -402.60 Cr |
| 2025-03-31 | 12.84 Cr | 0.00 Cr | 12.84 Cr | 177.10 Cr | 84.31 Cr | 303.87 Cr | 174.54 Cr | 588.03 Cr | 185.43 Cr |
| 2024-12-31 | 0.00 Cr | 0.00 Cr | 17.60 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | -412.01 Cr |
| 2024-09-30 | 9.70 Cr | 13.53 Cr | 23.23 Cr | 200.66 Cr | 64.55 Cr | 312.09 Cr | 176.57 Cr | 602.21 Cr | 190.20 Cr |
Quarterly Financials Cash Flow Statement
| Date | Net Income | Operating Cash Flow | Investing Cash Flow | Financing Cash Flow | Net Cash Change | Cash at End | Cash at Beginning | CapEx | Free Cash Flow |
|---|---|---|---|---|---|---|---|---|---|
| 2025-06-30 | -14.22 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2025-03-31 | -9.66 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-12-31 | 0.52 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-09-30 | 14.29 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-06-30 | 24.68 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
Splits History
| Date | Label | Split Ratio |
|---|---|---|
| 2023-10-10 | October 10, 23 | 10:1 |
Similar Stocks: Drug Manufacturers - Specialty & Generic
| Company Name | Symbol | Price | Market Cap | Volume |
|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | SUNPHARMA | ₹1,812.80 | ₹4,349,514,433,616.00 | ₹3,298,187.00 |
| Divi's Laboratories Limited | DIVISLAB | ₹6,372.00 | ₹1,691,565,791,760.00 | ₹298,134.00 |
| Torrent Pharmaceuticals Limited | TORNTPHARM | ₹4,427.80 | ₹1,498,568,719,232.00 | ₹373,853.00 |
| Dr. Reddy's Laboratories Limited | DRREDDY | ₹1,314.60 | ₹1,094,510,791,983.00 | ₹2,328,593.00 |
| Lupin Limited | LUPIN | ₹2,337.40 | ₹1,068,292,308,200.00 | ₹1,118,737.00 |
| Zydus Lifesciences Limited | ZYDUSLIFE | ₹923.10 | ₹928,854,596,169.00 | ₹548,985.00 |
| Mankind Pharma Limited | MANKIND | ₹2,237.70 | ₹923,733,909,614.00 | ₹1,043,890.00 |
| Aurobindo Pharma Limited | AUROPHARMA | ₹1,285.90 | ₹746,852,807,016.00 | ₹2,197,557.00 |
| Alkem Laboratories Limited | ALKEM | ₹5,616.50 | ₹671,536,822,500.00 | ₹127,559.00 |
| Glenmark Pharmaceuticals Limited | GLENMARK | ₹2,225.80 | ₹628,122,560,672.00 | ₹1,554,299.00 |
| Laurus Labs Limited | LAURUSLABS | ₹1,038.00 | ₹560,371,132,116.00 | ₹1,367,251.00 |
| Suven Pharmaceuticals Limited | SUVENPHAR | ₹1,078.00 | ₹412,407,234,624.00 | ₹1,177,218.00 |
| Ipca Laboratories Limited | IPCALAB | ₹1,491.20 | ₹378,323,729,882.00 | ₹56,999.00 |
| Ajanta Pharma Limited | AJANTPHARM | ₹2,999.90 | ₹374,794,378,438.00 | ₹123,025.00 |
| J. B. Chemicals & Pharmaceuticals Limited | JBCHEPHARM | ₹2,117.40 | ₹339,967,004,084.00 | ₹706,890.00 |
| Emcure Pharmaceuticals Ltd. | EMCURE | ₹1,567.80 | ₹297,211,828,212.00 | ₹871,597.00 |
| Piramal Enterprises Limited | PEL | ₹1,124.20 | ₹254,856,250,172.00 | ₹2,148,582.00 |
| AstraZeneca Pharma India Limited | ASTRAZEN | ₹8,815.50 | ₹220,387,500,000.00 | ₹3,477.00 |
| Wockhardt Limited | WOCKPHARMA | ₹1,327.40 | ₹215,692,105,131.00 | ₹576,727.00 |
| NATCO Pharma Limited | NATCOPHARM | ₹1,039.20 | ₹186,130,976,904.00 | ₹2,029,982.00 |
| Eris Lifesciences Limited | ERIS | ₹1,351.10 | ₹184,042,641,430.00 | ₹100,690.00 |
| Neuland Laboratories Limited | NEULANDLAB | ₹12,597.00 | ₹161,618,111,733.00 | ₹24,766.00 |
| Granules India Limited | GRANULES | ₹581.30 | ₹141,063,489,700.00 | ₹712,670.00 |
| Alembic Pharmaceuticals Limited | APLLTD | ₹712.35 | ₹140,021,741,381.00 | ₹50,451.00 |
| Glenmark Life Sciences Limited | GLS | ₹1,086.00 | ₹133,070,838,000.00 | ₹130,938.00 |
| Jubilant Pharmova Limited | JUBLPHARMA | ₹812.35 | ₹128,651,664,788.00 | ₹293,109.00 |
| Caplin Point Laboratories Limited | CAPLIPOINT | ₹1,684.10 | ₹128,011,297,234.00 | ₹43,345.00 |
| Alivus Life Sciences Ltd. | ALIVUS | ₹940.65 | ₹115,451,618,400.00 | ₹42,515.00 |
| Cohance Lifesciences Limited | COHANCE | ₹295.60 | ₹113,086,846,584.00 | ₹907,550.00 |
| Viyash Scientific Limited | VIYASH | ₹197.45 | ₹86,151,137,188.00 | ₹1,162,070.00 |
| Procter & Gamble Health Limited | PGHL | ₹4,892.10 | ₹81,205,836,682.00 | ₹11,986.00 |
| Strides Pharma Science Limited | STAR | ₹872.90 | ₹80,457,562,051.00 | ₹160,822.00 |
| Akums Drugs & Pharmaceuticals Ltd. | AKUMS | ₹500.60 | ₹76,642,890,235.00 | ₹265,090.00 |
| Shilpa Medicare Limited | SHILPAMED | ₹338.65 | ₹66,233,781,988.00 | ₹758,443.00 |
| Aarti Pharmalabs Limited | AARTIPHARM | ₹686.70 | ₹62,254,676,925.00 | ₹118,363.00 |
| FDC Limited | FDC | ₹378.05 | ₹61,550,352,256.00 | ₹52,686.00 |
| Sequent Scientific Limited | SEQUENT | ₹202.40 | ₹50,564,340,966.00 | ₹13,647.00 |
| Sun Pharma Advanced Research Company Limited | SPARC | ₹124.37 | ₹40,360,749,900.00 | ₹1,617,219.00 |
| Innova Captab Limited | INNOVACAP | ₹703.35 | ₹40,249,153,812.00 | ₹21,279.00 |
| Suven Life Sciences Limited | SUVEN | ₹144.43 | ₹33,500,801,218.00 | ₹421,279.00 |
| Gujarat Themis Biosyn Ltd. | GUJTHEM | ₹301.45 | ₹32,847,579,134.00 | ₹64,137.00 |
| Aarti Drugs Limited | AARTIDRUGS | ₹353.45 | ₹32,259,381,500.00 | ₹243,536.00 |
| RPG Life Sciences Limited | RPGLIFE | ₹1,908.60 | ₹31,566,364,029.00 | ₹7,443.00 |
| Gufic Biosciences Limited | GUFICBIO | ₹289.65 | ₹29,046,827,863.00 | ₹71,884.00 |
| Orchid Pharma Limited | ORCHPHARMA | ₹509.55 | ₹25,843,919,953.00 | ₹191,509.00 |
Key Executives
Executive Chairman
Dinesh Shantilal Patel
Gender: Not Specified
Year Born: 1948
Chief Executive Officer, MD & Executive Director
Sachin Dinesh Patel
Gender: Not Specified
Year Born: 1975
Senior General Manager of Chief Quality Assurance
Souvik Nandi
Gender: Not Specified
Year Born:
President of Plant
Damodar Reddy
Gender: male
Year Born:
Director of Legal & Compliance and Company Secretary
Pradeep Manjunath Chandan
Gender: male
Year Born:
General Manager of Operations
Raj Kumar
Gender: male
Year Born:
Chief Financial Officer
Tushar J. Dalal
Gender: male
Year Born:
Executive President - Sales & Marketing
Viraj Save
Gender: male
Year Born:
Assistant General Manager of Human Resource
Priti Nemani
Gender: female
Year Born:
Vice President of Systems & Administration and Alternate Non-Executive Non-Independent Director
Reena Sachin Patel
Gender: female
Year Born:
FAQs about Themis Medicare Limited
Who is the CEO of the company?
The CEO is Sachin Dinesh Patel.
What is the current market price of the stock?
The current price is ₹82.66.
What is the 52-week price range?
The range is ₹75.15-176.
What is the market capitalization of the company?
The market capitalization is ₹761.30 crores.
What is the dividend yield?
The dividend yield is 0.60%.
What is the Price-to-Earnings (P/E) ratio?
The P/E ratio is -43.74.
Which sector does the company belong to?
The company operates in the Healthcare sector.
What does the company do?
Overview of Themis Medicare Limited (ISIN: INE083B01024) is a leading Drug Manufacturers - Specialty & Generic in India. With a market capitalization of ₹761.30 crores and an average daily volume of 75,226 shares, it operates in the Drug Manufacturers - Specialty & Generic. The company last declared a dividend of ₹0.5.